Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

Abstract: The risk of relapse among high-risk patients with diffuse large B-cell lymphoma (DLBCL) in complete metabolic remission (CMR) after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy is 20% to 25%. Here, we evaluated whether consolidation with the prog...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcel Nijland, Djamila E. Issa, Johanna A. A. Bult, Dries Deeren, Gerjo A. Velders, Marten R. Nijziel, Yorick Sandberg, Vibeke Vergote, Margriet Oosterveld, Rob Fijnheer, Rolf E. Brouwer, Rinske S. Boersma, Kalung Wu, Laurens Nieuwenhuizen, Joost S. P. Vermaat, Roel J. W. van Kampen, Wim E. Terpstra, Sylvia Snauwaert, Marjolein W. van der Poel, Eva de Jongh, Marc F. Durian, Leonie Strobbe, Aart Beeker, Alain Gadisseur, Roos S. van Rijn, Otto Visser, Jeanette K. Doorduijn, Tjeerd J. F. Snijders, Matthijs H. Silbermann, Daphne de Jong, Martine Chamuleau, Rogier Mous, Hilde Jalving, Heleen Visser-Wisselaar, Sonja Jansen van de Bergh, Gerben J. C. Zwezerijnen, Edwin Bremer, Mirian Brink, Arjan Diepstra, Dana A. Chitu, Harry R. Koene, Josée M. Zijlstra
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002356
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items